Brief: Vaccinex Provides Update Of Potentially Pivotal Signal Clinical Trial In Huntington's Disease
07/07/2020 14:36
July 7 (Reuters) - Vaccinex Inc VCNX.O :
* VACCINEX PROVIDES UPDATE OF POTENTIALLY PIVOTAL SIGNAL
CLINICAL
TRIAL IN HUNTINGTON’S DISEASE
* VACCINEX INC - REMAINS ON TRACK TO COMPLETE POTENTIALLY
PIVOTAL
SIGNAL TRIAL IN HD WITHIN ANTICIPATED TIME FRAME
* VACCINEX INC - CONTINUES TO ANTICIPATE THAT DATABASE LOCK
WILL
BE COMPLETED BY SEPTEMBER
* VACCINEX INC - PRIMARY EFFICACY DATA HAS BEEN COLLECTED
FROM ALL
SUBJECTS WHO COMPLETED STUDY EXCEPT FOR 2 SUBJECTS
* VACCINEX INC - IDENTIFIED PRIMARY AND SECONDARY ENDPOINTS
FOR
TWO RANDOMIZED ARMS OF SIGNAL TRIAL
Source text for Eikon: ID:nGNX7dgxT4
Further company coverage: VCNX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease